The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

However, some research suggests that poor sleep could raise your risk of Alzheimer’s. A study published in November found ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two ...

According to the Alzheimer’s Association ( there are currently 6.5 million people with Alzheimer’s disease. An estimated 6.9 ...

Three common vaccines could potentially lower your risk of developing Alzheimer's disease and promote better brain health.

Groundbreaking study uncovers the crucial link between REM sleep patterns and Alzheimer's disease, providing new insights for ...

Taking longer to drift into the dreaming phase – known as rapid eye movement (REM) sleep – could be an early sign of Alzheimer's disease, potentially opening up new ways to diagnose and treat the ...